"I Wish to Continue Receiving the Reminder Short Messaging Service": A Mixed Methods Study on the Acceptability of Digital Adherence Tools Among Adults Living with HIV on Antiretroviral Treatment in Tanzania.
ART
DAT
SMS reminders
acceptability
adherence
digital adherence tool
real-time medication monitoring
Journal
Patient preference and adherence
ISSN: 1177-889X
Titre abrégé: Patient Prefer Adherence
Pays: New Zealand
ID NLM: 101475748
Informations de publication
Date de publication:
2021
2021
Historique:
received:
02
11
2020
accepted:
06
01
2021
entrez:
17
3
2021
pubmed:
18
3
2021
medline:
18
3
2021
Statut:
epublish
Résumé
Digital Adherence Tools (DAT) to promote adherence to antiretroviral treatment (ART) for HIV are being increasingly adopted globally, however their effectiveness and acceptability in limited resource settings has been challenging. In this study, we examine the acceptability of DATs to improve adherence to ART. This study was part of a three-arm randomized controlled trial (REMIND) which investigated the effect of two different DAT's: SMS text messages (SMS) or real-time medication monitoring (RTMM) on treatment adherence; compared to standard of care. Exit interviews and in-depth interviews were conducted at 48 weeks follow-up, to collect data on their experiences (successes, challenges, and barriers) and behaviours regarding the implementation of the interventions. Translated transcripts, memos and field notes were imported to NVivo software version 12. We used a thematic framework analysis which drew from Sekhon's theoretical framework of acceptability (TFA), which comprises of seven constructs (affective attitude, perceived burden, perceived effectiveness, ethicality, self-efficacy, intervention coherence and opportunity costs). Of the 166 participants enrolled, 143 (86%) were interviewed (68 in the SMS arm and 75 in the RTMM arm). Participants were highly satisfied (98%) with the DAT system and the majority of them reported it motivated them to take their medication (99%). The majority of participants reported they were confident in their ability to comply with the intervention and understood how the intervention worked (97%). Very few reported negatively about the devices (carrying the device), with only 6% reporting that they did not feel comfortable and 8% had ethical concerns with the SMS-content A few participants reported challenges with their connectivity/network and that the visits were too time-consuming. A few participants reported that they incurred extra cost for the sake of the study. Overall, the acceptability of these DATs was high. However, several factors may hamper their acceptability including the content and number of SMS, carrying the devices and the network availability.
Identifiants
pubmed: 33727801
doi: 10.2147/PPA.S290079
pii: 290079
pmc: PMC7955743
doi:
Types de publication
Journal Article
Langues
eng
Pagination
559-568Informations de copyright
© 2021 Ngowi et al.
Déclaration de conflit d'intérêts
Prof. Dr. Peter Reiss report grants from Gilead Sciences, ViiV Healthcare, Merck & Co, Scientific Advisory Board participation, honorarium paid to institution from Gilead Sciences, ViiV Healthcare, Merck & Co, and Teva Pharmaceutical Industries, outside the submitted work. The authors report no other conflicts of interest in this work.
Références
JMIR Form Res. 2020 Jun 10;4(6):e14649
pubmed: 32519966
AIDS Care. 2011 Feb;23(2):146-51
pubmed: 21259126
J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):e86-8
pubmed: 24442231
AIDS Behav. 2016 May;20(5):1097-107
pubmed: 26604004
BMC Med Inform Decis Mak. 2017 Feb 20;17(1):18
pubmed: 28219372
AIDS. 2016 May 15;30(8):1295-300
pubmed: 26760452
BMC Public Health. 2016 Jul 28;16:656
pubmed: 27465586
BMC Health Serv Res. 2017 Jan 26;17(1):88
pubmed: 28126032
Contemp Clin Trials. 2017 Jun;57:44-50
pubmed: 28315480
Patient Prefer Adherence. 2020 Jan 23;14:153-161
pubmed: 32021125
JMIR Mhealth Uhealth. 2020 Jul 8;8(7):e16925
pubmed: 32673267
AIDS. 2000 Mar 10;14(4):357-66
pubmed: 10770537
AIDS Behav. 2017 Feb;21(2):481-491
pubmed: 27858268
BMC Public Health. 2011 Feb 09;11:92
pubmed: 21306643
Malar J. 2017 Jan 25;16(1):46
pubmed: 28122622
PLoS One. 2012;7(12):e46909
pubmed: 23236345
Afr J Reprod Health. 2008 Aug;12(2):14-31
pubmed: 20695040
J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):578-84
pubmed: 25761233
Am J Health Promot. 1997 Sep-Oct;12(1):38-48
pubmed: 10170434
AIDS Behav. 2010 Dec;14(6):1340-6
pubmed: 20809380
BMJ Open. 2013 Jun 20;3(6):
pubmed: 23794578
BMC Infect Dis. 2018 Apr 11;18(1):171
pubmed: 29642874
Glob Health Sci Pract. 2019 Jun 27;7(2):171-188
pubmed: 31142546
Biochem Med (Zagreb). 2014;24(2):199-210
pubmed: 24969913
Glob Health Sci Pract. 2020 Mar 31;8(1):55-67
pubmed: 32139420
AIDS Care. 2018 Apr;30(4):500-505
pubmed: 29254362
Lancet Public Health. 2018 Mar;3(3):e143-e152
pubmed: 29361433
Ann Intern Med. 2000 Jul 4;133(1):21-30
pubmed: 10877736